Xanemems continued positive trajectory opposed to the decreasing placebo during follow up is a common theme throughout, would like to see a longer trial, or a second follow up.
- Forums
- ASX - By Stock
- ACW
- Ann: ACW XanaCIDD phase 2a trial topline results
Ann: ACW XanaCIDD phase 2a trial topline results, page-60
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
3.1¢ |
Change
-0.045(59.2%) |
Mkt cap ! $84.06M |
Open | High | Low | Value | Volume |
3.0¢ | 3.7¢ | 2.5¢ | $3.093M | 99.90M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 2638151 | 3.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.2¢ | 1623309 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 400000 | 0.033 |
2 | 68754 | 0.032 |
9 | 765287 | 0.031 |
8 | 1697272 | 0.030 |
8 | 1064705 | 0.029 |
Price($) | Vol. | No. |
---|---|---|
0.031 | 420093 | 4 |
0.032 | 2342401 | 9 |
0.033 | 2427203 | 11 |
0.034 | 1487252 | 6 |
0.035 | 3454058 | 10 |
Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online